{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:06:18Z","timestamp":1790802378854,"version":"4.1.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cgh.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T04:59:03Z","timestamp":1757825943000},"page":"1424-1433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-940X","authenticated-orcid":false,"given":"Remo","family":"Panaccione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil Y.","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Drobne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Kalabic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Rachel","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saajan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.09.007_bib1","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2025.09.007_bib2","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.09.007_bib3","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.09.007_bib4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/ibd\/izae004","article-title":"Extended induction and prognostic indicators of response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials","volume":"30","author":"D\u2019Haens","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2025.09.007_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/apt.17816","article-title":"Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis","volume":"59","author":"Panaccione","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2025.09.007_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.09.007_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","article-title":"Which do patients prefer? A systematic review","volume":"8","author":"Stoner","year":"2015","journal-title":"Patient"},{"key":"10.1016\/j.cgh.2025.09.007_bib8","first-page":"6","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe active ulcerative colitis receiving 16 weeks\u2019 extended induction treatment followed by 52 weeks\u2019 maintenance treatment in the U-ACHIEVE\/U-ACCOMPLISH trials","volume":"18","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525007979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525007979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:30:24Z","timestamp":1790800224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525007979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1542356525007979"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.09.007","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}